Neurology:多发性硬化:不同临床分型,对应的灰质受累类型各有不同

2021-03-27 Freemann MedSci原创

Neurology:多发性硬化:不同临床分型,对应的灰质受累类型各有不同

在过去的几十年里,灰质(GM)受累越来越被认为是多发性硬化症(MS)病理生理学的一个重要组成部分。GM萎缩发生在MS的最早阶段,并随着时间的推移而进展,复发-缓解性MS(RRMS)患者的萎缩率是对照组的倍,而进展性MS患者的萎缩率则高达倍。

一直以来,GM萎缩与临床残疾之间存在实质性关系。GM萎缩的区域分布在各表型中并不均匀,深GM和顶叶较早受累,在疾病后期,GM损失逐渐扩散到额叶、颞叶、枕叶和小脑区域。

意大利Vita-Salute San Raffaele University的Maria A. Rocca等人,使用基于源的形态测量(SBM),探究了GM萎缩特点以及这种萎缩在不同MS表型中的1年演变情况。

他们从8个欧洲站中心,纳入170名健康对照组(HCs)和398名MS患者(34名临床孤立综合征[CIS],226名复发缓解MS[RRMS],95名继发性进展性MS[SPMS],43名原发性进展性MS[PPMS])中获得临床和MRI数据。57名HC和144名MS患者进行了1年的随访。并评估了基线GM损失、萎缩进展以及与残疾和1年临床恶化的相关性。

他们通过SBM确定了26个小脑、皮质下、感觉、运动和认知GM成分。

和HC相比,在MS中,GM萎缩几乎在所有成分中都有发现;CIS患者表现出环状的皮质下、小脑、颞部和显著性GM萎缩,而RRMS患者表现出广泛的GM萎缩。

 

PPMS患者的小脑、皮层下、感觉运动、和额顶叶GM萎缩,SPMS与RRMS患者的GM萎缩。

1年时,21名(15%)患者临床病情恶化。MS中GM萎缩在皮质下、小脑、感觉运动和前颞顶叶成分中进展。基线较高的残疾与基线较低的正常化脑体积(β = -0.13,p = 0.001)、较大的感觉运动GM萎缩(β = -0.12,p = 0.002)和较长的病程(β = 0.09,p = 0.04)相关(R2 = 0.65)。

基线正常化GM体积(OR 0.98,p = 0.008)和小脑GM萎缩(OR0.40,p = 0.01)可独立预测临床恶化(曲线下面积0.83)。

这个研究的重要意义在于发现:GM萎缩在不同疾病表型中存在差异,并在MS后的一年中持续进展。除了全局性萎缩测量外,感觉运动和小脑的GM萎缩可以解释基线残疾和临床恶化。


原文出处:
Association of Gray Matter Atrophy Patterns With Clinical Phenotype and Progression in Multiple Sclerosis
Maria A. Rocca, Paola Valsasina, Alessandro Meani, et al.
Neurology Mar 2021, 96 (11) e1561-e1573; DOI: 10.1212/WNL.0000000000011494

版权声明:
本网站所有内容来源注明为“williamhill asia 医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于williamhill asia 医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“williamhill asia 医学”。其它来源的文章系转载文章,或“williamhill asia 号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与williamhill asia 联系,williamhill asia 将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1890233, encodeId=57cc1890233bd, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Fri Sep 10 06:48:04 CST 2021, time=2021-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001275, encodeId=0c2720012e516, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Wed Mar 02 12:48:04 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=952630, encodeId=692a9526307f, content=学到了很多东西谢谢老师, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c5b3006368, createdName=1436749007, createdTime=Wed Mar 31 13:57:26 CST 2021, time=2021-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951760, encodeId=ea67951e6088, content=学到了很多东西谢谢老师, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c5b3006368, createdName=1436749007, createdTime=Sun Mar 28 09:49:44 CST 2021, time=2021-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951525, encodeId=d324951525cb, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1e85452631, createdName=ms2000001220304954, createdTime=Sat Mar 27 07:55:36 CST 2021, time=2021-03-27, status=1, ipAttribution=)]
    2021-09-10 jml2009
  2. [GetPortalCommentsPageByObjectIdResponse(id=1890233, encodeId=57cc1890233bd, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Fri Sep 10 06:48:04 CST 2021, time=2021-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001275, encodeId=0c2720012e516, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Wed Mar 02 12:48:04 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=952630, encodeId=692a9526307f, content=学到了很多东西谢谢老师, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c5b3006368, createdName=1436749007, createdTime=Wed Mar 31 13:57:26 CST 2021, time=2021-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951760, encodeId=ea67951e6088, content=学到了很多东西谢谢老师, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c5b3006368, createdName=1436749007, createdTime=Sun Mar 28 09:49:44 CST 2021, time=2021-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951525, encodeId=d324951525cb, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1e85452631, createdName=ms2000001220304954, createdTime=Sat Mar 27 07:55:36 CST 2021, time=2021-03-27, status=1, ipAttribution=)]
    2022-03-02 yinhl1978
  3. [GetPortalCommentsPageByObjectIdResponse(id=1890233, encodeId=57cc1890233bd, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Fri Sep 10 06:48:04 CST 2021, time=2021-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001275, encodeId=0c2720012e516, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Wed Mar 02 12:48:04 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=952630, encodeId=692a9526307f, content=学到了很多东西谢谢老师, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c5b3006368, createdName=1436749007, createdTime=Wed Mar 31 13:57:26 CST 2021, time=2021-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951760, encodeId=ea67951e6088, content=学到了很多东西谢谢老师, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c5b3006368, createdName=1436749007, createdTime=Sun Mar 28 09:49:44 CST 2021, time=2021-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951525, encodeId=d324951525cb, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1e85452631, createdName=ms2000001220304954, createdTime=Sat Mar 27 07:55:36 CST 2021, time=2021-03-27, status=1, ipAttribution=)]
    2021-03-31 1436749007

    学到了很多东西谢谢老师

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1890233, encodeId=57cc1890233bd, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Fri Sep 10 06:48:04 CST 2021, time=2021-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001275, encodeId=0c2720012e516, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Wed Mar 02 12:48:04 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=952630, encodeId=692a9526307f, content=学到了很多东西谢谢老师, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c5b3006368, createdName=1436749007, createdTime=Wed Mar 31 13:57:26 CST 2021, time=2021-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951760, encodeId=ea67951e6088, content=学到了很多东西谢谢老师, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c5b3006368, createdName=1436749007, createdTime=Sun Mar 28 09:49:44 CST 2021, time=2021-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951525, encodeId=d324951525cb, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1e85452631, createdName=ms2000001220304954, createdTime=Sat Mar 27 07:55:36 CST 2021, time=2021-03-27, status=1, ipAttribution=)]
    2021-03-28 1436749007

    学到了很多东西谢谢老师

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1890233, encodeId=57cc1890233bd, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Fri Sep 10 06:48:04 CST 2021, time=2021-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001275, encodeId=0c2720012e516, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Wed Mar 02 12:48:04 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=952630, encodeId=692a9526307f, content=学到了很多东西谢谢老师, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c5b3006368, createdName=1436749007, createdTime=Wed Mar 31 13:57:26 CST 2021, time=2021-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951760, encodeId=ea67951e6088, content=学到了很多东西谢谢老师, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c5b3006368, createdName=1436749007, createdTime=Sun Mar 28 09:49:44 CST 2021, time=2021-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951525, encodeId=d324951525cb, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1e85452631, createdName=ms2000001220304954, createdTime=Sat Mar 27 07:55:36 CST 2021, time=2021-03-27, status=1, ipAttribution=)]
    2021-03-27 ms2000001220304954

    学习了

    0

相关威廉亚洲官网

NEJM:Ide-cel治疗复发性多发性骨髓瘤患者II期临床获得成功

超过7成的难治性和复发性骨髓瘤患者在接受ide-cel治疗后有应答,其中近3成患者实现微小残留疾病阴性,几乎所有患者出现3级或4级不良事件,最常见的是血液学毒性和细胞因子释放综合征

CHMP建议批准Sarclisa(isatuximab)与卡非佐米和地塞米松联合治疗复发性多发性骨髓瘤

与单独使用Kd相比,Sarclisa联合Kd将患者的疾病进展或死亡风险降低了47%。

Nat Med:多发性骨髓瘤患者在BCMA靶向CAR-T治疗后或引起BCMA纯合缺失

B细胞成熟抗原(BCMA)作为多种免疫疗法的靶点,也是多发性骨髓瘤(MM)中与肿瘤负荷相关的生物标志物。

Eur Radiol:如何评价多发性骨髓瘤的结构与异质性?

将纹理分析技术应用在多发性骨髓瘤CT图像上,可以获得更多的信息,从而更准确地表征肿瘤的结构和异质性。

FDA批准PEPAXTO(美法仑氟苯甲酰胺)用于治疗复发难治多发性骨髓瘤

PEPAXTO是一款抗癌肽-药物偶联物(PDC),其靶向氨基肽酶并将烷基化剂迅速释放到肿瘤细胞中。

AACR 2021:抗CD47抗体AO-176治疗实体瘤和多发性骨髓瘤,临床前试验取得积极结果

生物技术公司Arch Oncology今天宣布,在美国癌症研究协会(AACR)年会上介绍了AO-176的最新临床前数据。